LOPD
MCID: HRD173
MIFTS: 43

Hereditary Late-Onset Parkinson Disease (LOPD)

Categories: Genetic diseases, Mental diseases, Metabolic diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hereditary Late-Onset Parkinson Disease

MalaCards integrated aliases for Hereditary Late-Onset Parkinson Disease:

Name: Hereditary Late-Onset Parkinson Disease 58
Autosomal Dominant Late-Onset Parkinson Disease 58
Lopd 58

Characteristics:

Orphanet epidemiological data:

58
hereditary late-onset parkinson disease
Inheritance: Autosomal dominant; Age of onset: Adult,Elderly; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Hereditary Late-Onset Parkinson Disease

MalaCards based summary : Hereditary Late-Onset Parkinson Disease, also known as autosomal dominant late-onset parkinson disease, is related to glycogen storage disease ii and myopathy. An important gene associated with Hereditary Late-Onset Parkinson Disease is DNAJC13 (DnaJ Heat Shock Protein Family (Hsp40) Member C13), and among its related pathways/superpathways is Parkinsons Disease Pathway. The drugs mometasone furoate and Miglustat have been mentioned in the context of this disorder. Affiliated tissues include tongue, liver and brain, and related phenotypes are diplopia and dysphagia

Related Diseases for Hereditary Late-Onset Parkinson Disease

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 1, Autosomal Dominant Parkinson Disease 15, Autosomal Recessive Early-Onset
Parkinson Disease 12 Parkinson Disease 2, Autosomal Recessive Juvenile
Parkinson Disease 3, Autosomal Dominant Parkinson Disease 4, Autosomal Dominant
Parkinson Disease 6, Autosomal Recessive Early-Onset Parkinson Disease 7, Autosomal Recessive Early-Onset
Parkinson Disease 10 Parkinson Disease 8, Autosomal Dominant
Parkinson Disease 11, Autosomal Dominant Parkinson Disease 13, Autosomal Dominant
Parkinson Disease 14, Autosomal Recessive Parkinson Disease 16
Parkinson Disease 5, Autosomal Dominant Parkinson Disease 17
Parkinson Disease 18, Autosomal Dominant Parkinson Disease 19a, Juvenile-Onset
Parkinson Disease 20, Early-Onset Parkinson Disease 21
Parkinson Disease 22, Autosomal Dominant Parkinson Disease 23, Autosomal Recessive Early-Onset
Juvenile-Onset Parkinson's Disease Early-Onset Parkinson's Disease
Vps35-Related Parkinson Disease Hereditary Late-Onset Parkinson Disease

Diseases related to Hereditary Late-Onset Parkinson Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
# Related Disease Score Top Affiliating Genes
1 glycogen storage disease ii 10.7
2 myopathy 10.4
3 muscular dystrophy 10.3
4 muscular dystrophy, duchenne type 10.1
5 intracranial aneurysm 10.1
6 respiratory failure 10.1
7 hypertrophic cardiomyopathy 10.1
8 encephalopathy 10.1
9 hypotonia 10.1
10 lrrk2 parkinson disease 10.1 SNCA LRRK2
11 parkinson disease 10 10.1 SNCA LRRK2
12 parkinson disease 3, autosomal dominant 10.0 SNCA LRRK2
13 postencephalitic parkinson disease 10.0 SNCA LRRK2
14 parkinson disease 2, autosomal recessive juvenile 10.0 SNCA LRRK2
15 aphasia 9.9 SNCA LRRK2
16 multiple system atrophy 1 9.9 SNCA LRRK2
17 toxic encephalopathy 9.9 SNCA LRRK2
18 supranuclear palsy, progressive, 1 9.8 SNCA LRRK2
19 corticobasal degeneration 9.7 LRRK2 GBA
20 juvenile-onset parkinson's disease 9.7 VPS35 SNCA LRRK2
21 parkinson disease 15, autosomal recessive early-onset 9.7 VPS35 SNCA LRRK2
22 kufor-rakeb syndrome 9.7 VPS35 SNCA LRRK2
23 krabbe disease 9.7 SNCA GBA
24 mitochondrial complex i deficiency, nuclear type 1 9.6 SNCA LRRK2 GIGYF2
25 gaucher's disease 9.5 SNCA GBA
26 dysautonomia 9.5 SNCA GBA DNAJC13
27 dementia 9.5 SNCA LRRK2 GBA
28 rem sleep behavior disorder 9.5 SNCA LRRK2 GBA
29 leukoencephalopathy with vanishing white matter 9.4 SNCA EIF4G1
30 sphingolipidosis 9.4 SNCA LRRK2 GBA
31 movement disease 9.4 SNCA LRRK2 GBA
32 tremor 9.2 SNCA LRRK2 GBA DNAJC13
33 essential tremor 9.2 SNCA LRRK2 GBA DNAJC13
34 early-onset parkinson's disease 9.1 SNCA LRRK2 GIGYF2 GBA
35 dementia, lewy body 9.1 VPS35 SNCA LRRK2 GBA
36 parkinson disease, late-onset 7.9 VPS35 SNCA LRRK2 GIGYF2 GBA EIF4G1

Graphical network of the top 20 diseases related to Hereditary Late-Onset Parkinson Disease:



Diseases related to Hereditary Late-Onset Parkinson Disease

Symptoms & Phenotypes for Hereditary Late-Onset Parkinson Disease

Human phenotypes related to Hereditary Late-Onset Parkinson Disease:

58 31 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diplopia 58 31 frequent (33%) Frequent (79-30%) HP:0000651
2 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
3 chronic constipation 58 31 frequent (33%) Frequent (79-30%) HP:0012450
4 frequent falls 58 31 frequent (33%) Frequent (79-30%) HP:0002359
5 hyposmia 58 31 frequent (33%) Frequent (79-30%) HP:0004409
6 parkinsonism with favorable response to dopaminergic medication 58 31 frequent (33%) Frequent (79-30%) HP:0002548
7 akinesia 58 31 frequent (33%) Frequent (79-30%) HP:0002304
8 spastic/hyperactive bladder 58 31 frequent (33%) Frequent (79-30%) HP:0005340
9 resting tremor 58 31 frequent (33%) Frequent (79-30%) HP:0002322
10 sleep disturbance 58 31 occasional (7.5%) Occasional (29-5%) HP:0002360
11 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
12 dyskinesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100660
13 cerebral cortical atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002120
14 hypomimic face 58 31 occasional (7.5%) Occasional (29-5%) HP:0000338
15 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
16 dystonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001332
17 rigidity 58 31 occasional (7.5%) Occasional (29-5%) HP:0002063
18 agitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0000713
19 visual hallucinations 58 31 occasional (7.5%) Occasional (29-5%) HP:0002367
20 impulsivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0100710
21 bradykinesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002067
22 shuffling gait 58 31 occasional (7.5%) Occasional (29-5%) HP:0002362
23 orthostatic hypotension due to autonomic dysfunction 58 31 occasional (7.5%) Occasional (29-5%) HP:0004926
24 gliosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002171
25 apathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000741
26 postural instability 58 31 occasional (7.5%) Occasional (29-5%) HP:0002172
27 monotonic speech 58 31 occasional (7.5%) Occasional (29-5%) HP:0031435
28 lewy bodies 58 31 occasional (7.5%) Occasional (29-5%) HP:0100315
29 low frustration tolerance 58 31 occasional (7.5%) Occasional (29-5%) HP:0000744
30 muscle spasm 31 occasional (7.5%) HP:0003394
31 dementia 58 31 very rare (1%) Very rare (<4-1%) HP:0000726
32 schizophrenia 58 31 very rare (1%) Very rare (<4-1%) HP:0100753
33 muscle cramps 58 Occasional (29-5%)
34 mental deterioration 58 Occasional (29-5%)
35 parkinsonism 58 Obligate (100%)

MGI Mouse Phenotypes related to Hereditary Late-Onset Parkinson Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.26 EIF4G1 LRRK2 SNCA VPS35
2 normal MP:0002873 9.02 EIF4G1 GBA LRRK2 SNCA VPS35

Drugs & Therapeutics for Hereditary Late-Onset Parkinson Disease

Drugs for Hereditary Late-Onset Parkinson Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
2
Miglustat Approved Phase 3 72599-27-0 51634
3 Hypoglycemic Agents Phase 3
4 Anti-Infective Agents Phase 3
5 Anti-Retroviral Agents Phase 3
6 Antiviral Agents Phase 3
7 Cardiac Glycosides Phase 3
8 Glycoside Hydrolase Inhibitors Phase 3
9 Anti-HIV Agents Phase 3
10
Clenbuterol Approved, Investigational, Vet_approved Phase 2 37148-27-9 2783
11 Tocolytic Agents Phase 1, Phase 2
12 Albuterol Phase 1, Phase 2
13 Neurotransmitter Agents Phase 2
14 Sympathomimetics Phase 2
15 Adrenergic Agonists Phase 2
16 Respiratory System Agents Phase 2
17 Anti-Asthmatic Agents Phase 2
18 Adrenergic beta-Agonists Phase 2
19 Autonomic Agents Phase 2
20 Bronchodilator Agents Phase 2
21 Adrenergic Agents Phase 2
22
Acetaminophen Approved Phase 1 103-90-2 1983
23
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
24
tannic acid Approved Phase 1 1401-55-4
25
Lidocaine Approved, Vet_approved Phase 1 137-58-6 3676
26
Histamine Approved, Investigational Phase 1 51-45-6 774
27
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
28
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
29
Diphenhydramine Approved, Investigational Phase 1 147-24-0, 58-73-1 3100
30
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
31
rituximab Approved Phase 1 174722-31-7 10201696
32
Promethazine Approved, Investigational Phase 1 60-87-7 4927
33 Immunologic Factors Phase 1
34 Antibodies Phase 1
35 Immunoglobulins Phase 1
36 Immunosuppressive Agents Phase 1
37 Anesthetics, Local Phase 1
38 Anti-Arrhythmia Agents Phase 1
39 Antiemetics Phase 1
40 Gastrointestinal Agents Phase 1
41 Antineoplastic Agents, Immunological Phase 1
42 Anesthetics Phase 1
43 Sodium Channel Blockers Phase 1
44 Antipyretics Phase 1
45 Analgesics, Non-Narcotic Phase 1
46 Antibiotics, Antitubercular Phase 1
47 Hypnotics and Sedatives Phase 1
48 Histamine H1 Antagonists Phase 1
49 Dermatologic Agents Phase 1
50 Antifungal Agents Phase 1

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo Recruiting NCT03729362 Phase 3 AT2221
2 An Open-label Study of the Pharmacokinetics, Safety, Efficacy, and Pharmacodynamics of ATB200/AT2221 in Pediatric Subjects Aged 12 to < 18 Years With Late-onset Pompe Disease Recruiting NCT03911505 Phase 3 AT2221
3 A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Not yet recruiting NCT04138277 Phase 3 AT2221
4 A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy Completed NCT01885936 Phase 1, Phase 2 Albuterol;Placebo
5 A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy Completed NCT01942590 Phase 1, Phase 2 Clenbuterol;Placebo
6 Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease Stably Treated With Enzyme Replacement Therapy Not yet recruiting NCT04094948 Phase 2 Clenbuterol;Placebos
7 A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease Not yet recruiting NCT04174105 Phase 1, Phase 2
8 A Study of Repiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD) Terminated NCT02191917 Phase 2
9 A Clinical Investigation of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease, Whether or Not Receiving Enzyme Replacement Therapy Completed NCT01859624 Phase 1 Albuterol
10 Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD) Recruiting NCT02240407 Phase 1 Rapamycin;Rituxan;Diphenhydramine;Acetaminophen;Lidocaine;LMX 4 Topical Cream
11 Function, Structure and Quality of Striated Muscles in Patients With Muscular Diseases - an MRI Study on Pompe Disease and Dystrophia Myotonica Unknown status NCT02708784
12 Determining the Diagnostic Utility of the Identification of Tongue Involvement in Late-Onset Pompe Disease (LOPD) Completed NCT02765828
13 Respiratory Muscle Training in Late-Onset Pompe Disease Completed NCT02801539
14 Epidemiological, Observational, Retrospective and Multicenter Study to Evaluate the Characteristics of Treatment With Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma Treated in the First Line in Routine Clinical Practice. ANICE-PaC Study Completed NCT03620461 Gemcitabine - nabpaclitaxel
15 Study of the Efficiency and Workflow of Femtosecond Laser Assisted Cataract Surgery in a Spanish Public Hospital Completed NCT03931629
16 Lingual Muscle Training in Late-Onset Pompe Disease (LOPD) Recruiting NCT03255213
17 A Multi-Center, Low-Interventional Study With a Retrospective Component in Participants With Late-Onset Pompe Disease Recruiting NCT03893240
18 Developing a Management Approach for Patients With "Late-Onset" Pompe Disease GAA Variant Identified by Newborn Screening Recruiting NCT03694561
19 Open Randomised Multicentric Controlled Trial to Evaluate the Impact of an Intervention to Improve Drug Appropriateness in Polymedicated Patients According to the Person-centered Care Model by a Multidisciplinary Team at Primary Care Not yet recruiting NCT04188470
20 A Prospective Study in Subjects With Late Onset Pompe Disease Who Are Currently Being Treated With Enzyme Replacement Therapy Terminated NCT03347253

Search NIH Clinical Center for Hereditary Late-Onset Parkinson Disease

Genetic Tests for Hereditary Late-Onset Parkinson Disease

Anatomical Context for Hereditary Late-Onset Parkinson Disease

MalaCards organs/tissues related to Hereditary Late-Onset Parkinson Disease:

40
Tongue, Liver, Brain, Testes, Bone, Skeletal Muscle, Kidney

Publications for Hereditary Late-Onset Parkinson Disease

Articles related to Hereditary Late-Onset Parkinson Disease:

(show top 50) (show all 261)
# Title Authors PMID Year
1
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. 61 6
17050822 2006
2
VPS35-Related Parkinson Disease 6
28796472 2017
3
Identification of TMEM230 mutations in familial Parkinson's disease. 6
27270108 2016
4
EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts. 6
25368108 2015
5
The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity. 6
24695735 2014
6
DNAJC13 mutations in Parkinson disease. 6
24218364 2014
7
Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. 6
23408866 2013
8
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. 6
23279440 2013
9
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. 6
23075850 2012
10
Frequency of the D620N mutation in VPS35 in Parkinson disease. 6
22801713 2012
11
VPS35 mutation in Japanese patients with typical Parkinson's disease. 6
22991136 2012
12
Identification of VPS35 mutations replicated in French families with Parkinson disease. 6
22517097 2012
13
Translation initiator EIF4G1 mutations in familial Parkinson disease. 6
21907011 2011
14
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. 6
21763483 2011
15
Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. 6
21115957 2010
16
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. 6
20186690 2010
17
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. 6
20008657 2009
18
Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. 6
19283415 2009
19
Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. 6
19308469 2009
20
Non-synonymous GIGYF2 variants in Parkinson's disease from two Asian populations. 6
19449032 2009
21
PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. 6
19250854 2009
22
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. 6
19667187 2009
23
Variation in GIGYF2 is not associated with Parkinson disease. 6
19279319 2009
24
LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. 6
19020907 2009
25
Lack of replication of association between GIGYF2 variants and Parkinson disease. 6
18923002 2009
26
Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? 6
18981379 2008
27
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. 6
18704525 2008
28
Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. 6
18342564 2008
29
Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. 6
18358451 2008
30
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? 6
17938369 2007
31
Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians. 6
17659642 2007
32
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. 6
17215492 2007
33
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. 6
17251522 2007
34
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. 6
17353388 2007
35
The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. 6
17019612 2007
36
LRRK2 Parkinson Disease 6
20301387 2006
37
LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. 6
17060595 2006
38
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. 6
16960813 2006
39
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. 6
16966502 2006
40
Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. 6
16728648 2006
41
A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. 6
16633828 2006
42
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. 6
16533964 2006
43
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. 6
16436781 2006
44
Analysis of the LRRK2 G2019S mutation in Alzheimer Disease. 6
16401756 2006
45
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. 6
16321986 2006
46
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. 6
16436782 2006
47
Lrrk2 pathogenic substitutions in Parkinson's disease. 6
16172858 2005
48
Genetics of Parkinson's disease: LRRK2 on the rise. 6
16311269 2005
49
G2019S LRRK2 mutation in French and North African families with Parkinson's disease. 6
16240353 2005
50
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. 6
16269541 2005

Variations for Hereditary Late-Onset Parkinson Disease

Expression for Hereditary Late-Onset Parkinson Disease

Search GEO for disease gene expression data for Hereditary Late-Onset Parkinson Disease.

Pathways for Hereditary Late-Onset Parkinson Disease

Pathways related to Hereditary Late-Onset Parkinson Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.55 SNCA LRRK2

GO Terms for Hereditary Late-Onset Parkinson Disease

Cellular components related to Hereditary Late-Onset Parkinson Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.02 VPS35 SNCA LRRK2 GIGYF2 GBA EIF4G1
2 Golgi apparatus GO:0005794 9.73 SNCA LRRK2 GIGYF2 GBA
3 neuronal cell body GO:0043025 9.58 VPS35 SNCA LRRK2
4 endosome GO:0005768 9.56 VPS35 LRRK2 GIGYF2 DNAJC13
5 lysosomal membrane GO:0005765 9.5 VPS35 GBA DNAJC13
6 synaptic vesicle membrane GO:0030672 9.46 SNCA LRRK2
7 terminal bouton GO:0043195 9.37 SNCA LRRK2
8 inclusion body GO:0016234 9.16 SNCA LRRK2
9 postsynapse GO:0098794 9.13 VPS35 SNCA LRRK2
10 lysosome GO:0005764 8.92 VPS35 SNCA LRRK2 GBA

Biological processes related to Hereditary Late-Onset Parkinson Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cellular response to oxidative stress GO:0034599 9.58 SNCA LRRK2
2 mitochondrion organization GO:0007005 9.58 LRRK2 GBA
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.57 SNCA EIF4G1
4 regulation of protein stability GO:0031647 9.56 VPS35 LRRK2
5 negative regulation of protein phosphorylation GO:0001933 9.55 SNCA LRRK2
6 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.54 LRRK2 GBA
7 regulation of macroautophagy GO:0016241 9.52 VPS35 GBA
8 cellular response to starvation GO:0009267 9.51 LRRK2 GBA
9 excitatory postsynaptic potential GO:0060079 9.49 SNCA LRRK2
10 adult locomotory behavior GO:0008344 9.48 SNCA GIGYF2
11 protein destabilization GO:0031648 9.46 VPS35 SNCA
12 regulation of neuron death GO:1901214 9.43 SNCA LRRK2
13 lysosome organization GO:0007040 9.43 VPS35 LRRK2 GBA
14 regulation of locomotion GO:0040012 9.4 SNCA LRRK2
15 regulation of cellular protein metabolic process GO:0032268 9.37 VPS35 GBA
16 positive regulation of dopamine receptor signaling pathway GO:0060161 9.32 VPS35 LRRK2
17 negative regulation of late endosome to lysosome transport GO:1902823 9.16 VPS35 LRRK2
18 regulation of presynapse assembly GO:1905606 9.13 VPS35 SNCA EIF4G1
19 negative regulation of neuron death GO:1901215 9.02 VPS35 SNCA LRRK2 GBA EIF4G1

Molecular functions related to Hereditary Late-Onset Parkinson Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SNARE binding GO:0000149 8.62 SNCA LRRK2

Sources for Hereditary Late-Onset Parkinson Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....